Efficacy of Bacteriophages in a Staphylococcus aureus Nondiabetic or Diabetic Foot Infection Murine Model

Albac, Sandrine; Medina, Mathieu; Labrousse, Delphine; Hayez, Davy; Bonnot, Dorian; Anzala, Nelson; Laurent, Frédéric; Ferry, Tristan; Dublanchet, A.; Chavanet, P.; Fèvre, Cindy; Croisier, Delphine

doi:10.1128/aac.01870-19

Cited by 14 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, despite phage potentially having synergistic effects with antibiotics in vitro and in vivo [ 61 , 65 ], several issues should be first resolved for its clinical application and a greater focus on the decrease of the possible harm to humans warrants investigation in further research.…”

Section: Discussionmentioning

confidence: 99%

Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics

Wei

et al. 2021

Antibiotics

View full text Add to dashboard Cite

Staphylococcus aureus phage Henu2 was isolated from a sewage sample collected in Kaifeng, China, in 2017. In this study, Henu2, a linear double-stranded DNA virus, was sequenced and found to be 43513bp long with 35% G + C content and 63 putative open reading frames (ORFs). Phage Henu2 belongs to the family Siphoviridae and possesses an isometric head (63 nm in diameter). The latent time and burst size of Henu2 were approximately 20 min and 7.8 plaque forming unit (PFU)/infected cells. The Henu2 maintained infectivity over a wide range of temperature (10–60 °C) and pH values (4–12). Phylogenetic and comparative genomic analyses indicate that Staphylococcus aureus phage Henu2 should be a new member of the family of Siphoviridae class-II. In this paper, Phage Henu2 alone exhibited weak inhibitory activity on the growth of S. aureus. However, the combination of phage Henu2 and some antibiotics or oxides could effectively inhibit the growth of S. aureus, with a decrease of more than three logs within 24 h in vitro. These results provide useful information that phage Henu2 can be combined with antibiotics to increase the production of phage Henu2 and thus enhance the efficacy of bacterial killing.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics

Wei

et al. 2021

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Injection into or near local infections (Wills et al, 2005;Gill et al, 2006;Capparelli et al, 2007;Bhowmick et al, 2009;Alam et al, 2011;Chhibber et al, 2013;Trigo et al, 2013;Basu et al, 2015;Kishor et al, 2016;Breyne et al, 2017;Chhibber et al, 2017;Yin et al, 2017;Albac et al, 2020;Geng et al, 2020) Międzybrodzki et al, 2009, in which phages were applied topically to humans, potentially in a variety though nonetheless not explicitly described contexts.…”

Section: (7)mentioning

confidence: 99%

Phage Therapy: The Pharmacology of Antibacterial Viruses

Danis-Wlodarczyk¹,

Dąbrowska²,

Abedon³

2021

Current Issues in Molecular Biology

View full text Add to dashboard Cite

Pharmacology can be differentiated into two key aspects, pharmacodynamics and pharmacokinetics. Pharmacodynamics describes a drug's impact on the body while pharmacokinetics describes the body's impact on a drug. Another way of understanding these terms is that pharmacodynamics is a description of both the positive and negative consequences of drugs attaining certain concentrations in the body while pharmacokinetics is concerned with our ability to reach and then sustain those concentrations. Unlike the drugs for which these concepts were developed, including antibiotics, the bacteriophages (or 'phages') that we consider here are not chemotherapeutics but instead are the viruses of bacteria. Here we review the pharmacology of these viruses, particularly as they can be employed to combat bacterial infections (phage therapy). Overall, an improved pharmacological understanding of phage therapy should allow for more informed development of phages as antibacterial 'drugs', allow for more rational post hoc debugging of phage therapy experiments, and encourage improved design of phage therapy protocols. Contrasting with antibiotics, however, phages as viruses impact individual bacterial cells as single virions rather than as swarms of molecules, and while they are killing bacteria, caister.com/cimb 81 Curr. Issues Mol. Biol. Vol. 40bacteriophages also can amplify phage numbers, in situ. Explorations of phage therapy pharmacology consequently can often be informed as well by basic principles of the ecological interactions between phages and bacteria as by study of the pharmacology of drugs. Bacteriophages in phage therapy thus can display somewhat unique as well as more traditional pharmacological aspects.

show abstract

“…Antibiotics are mainly empirical in the first instance, in accordance with the causative pathogen and the severity of the infection. The definitive antibiotic treatment is changed according to the microbiological culture and the response of the Mendes et al, 2014;Fish et al, 2018;Hill et al, 2018;Morozova et al, 2018;Taha et al, 2018;Albac et al, 2020;Kifelew et al, -Improve closure time Kanji and Das, 2017;Lo et al, 2019;Lintzeris et al, 2018;Mao et al, 2018;Momeni et al, 2019;Hassanshahi et al, 2019;Hwang et al, 2019;Oropallo, 2019 3D-printed empirical treatment (Kwon and Armstrong, 2018). Its duration will depend on the severity of the infection.…”

Section: Antimicrobial Therapy For Infected Diabetic Foot Ulcersmentioning

confidence: 99%

Alternative Approaches for the Management of Diabetic Foot Ulcers

et al. 2021

View full text Add to dashboard Cite

Diabetic foot ulcers (DFU) represent a growing public health problem. The emergence of multidrug-resistant (MDR) bacteria is a complication due to the difficulties in distinguishing between infection and colonization in DFU. Another problem lies in biofilm formation on the skin surface of DFU. Biofilm is an important pathophysiology step in DFU and may contribute to healing delays. Both MDR bacteria and biofilm producing microorganism create hostile conditions to antibiotic action that lead to chronicity of the wound, followed by infection and, in the worst scenario, lower limb amputation. In this context, alternative approaches to antibiotics for the management of DFU would be very welcome. In this review, we discuss current knowledge on biofilm in DFU and we focus on some new alternative solutions for the management of these wounds, such as antibiofilm approaches that could prevent the establishment of microbial biofilms and wound chronicity. These innovative therapeutic strategies could replace or complement the classical strategy for the management of DFU to improve the healing process.

show abstract

Efficacy of Bacteriophages in a Staphylococcus aureus Nondiabetic or Diabetic Foot Infection Murine Model

Cited by 14 publications

References 9 publications

Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics

Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics

Phage Therapy: The Pharmacology of Antibacterial Viruses

Alternative Approaches for the Management of Diabetic Foot Ulcers

Contact Info

Product

Resources

About